• To make a donation on-line to the HemOnc Research Acceleration Fund, directly supporting UAB Hematology/Oncology Research-Related Activities, click here.

Or, for a printable version of the donation form, click donor card RAF.

The Division of Hematology and Oncology has basic research programs in the areas of cancer genetics, TGF-β signaling, transcriptional regulation, tumor suppressor gene biology, oncogene expression and function, signal transduction, antibody-mediated destruction of hematologic and malignant cells, chemotherapeutic agent pharmacology, and use of electromagnetic fields for the treatment of cancer. The majority of our faculty has independent research funding in these areas.

Investigator-initiated clinical studies include novel treatment modalities such as the anti-DR5 antibody and gdT-cells, pharmacologic studies of chemotherapy agents, regional chemotherapy, combined modality treatment (chemotherapy, radiation therapy, and surgery), growth factors, diagnostic and therapeutic use of monoclonal antibodies and use of amplitude-modulated electromagnetic fields for the treatment of cancer.

Division of Hematology-Oncology Recent Publications 








    • Samanta, D., Kauffmann, J., Carbone D.P., and Datta, P.K., Long-term smoking mediated downregulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer. Neoplasia, 14(7): 644-655, 2012.
    • Lamb LS, Bowersock J, Dasgupta A, Gillespie GY, Su Y, Johnson A, Spencer HT Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: A strategy for combining chemo- and immunotherapy PloS One December 2012.
    • Nagathihali, N.S., Massion, P., Gonjalez, A, and Datta, P.K., Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Molecular Cancer Therapeutics, 11(11):2362-2372, 2012.